Loges Sonja, Schmidt Thomas, Carmeliet Peter
Vesalius Research Center (VRC), Leuven, Belgium.
Genes Cancer. 2010 Jan;1(1):12-25. doi: 10.1177/1947601909356574.
The concept of inhibiting tumor neovessels has taken the hurdle from the bench to the bedside and now represents an extra pillar of anticancer treatment. So far, anti-angiogenic therapy prolongs survival in the order of months in some settings while failing to induce a survival benefit in others, in part because of intrinsic refractoriness or evasive escape. This review provides an update on recent mechanisms via which tumor and stromal cells induce resistance and discusses recent evolutions in the (pre)clinical development of novel third-generation anti-angiogenic agents to overcome this problem.
抑制肿瘤新生血管的概念已跨越从实验室到临床应用的障碍，如今成为抗癌治疗的又一重要支柱。到目前为止，抗血管生成疗法在某些情况下能将生存期延长数月，而在其他情况下则无法带来生存获益，部分原因是存在内在难治性或逃避现象。本综述提供了关于肿瘤和基质细胞诱导耐药的最新机制的最新信息，并讨论了新型第三代抗血管生成药物在（临床前）临床开发中为克服这一问题的最新进展。
